Search

Cevimeline

It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome. … Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

Tasadenoturev

Thymidine

[A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent. … Thymidine is a naturally occurring deoxyribonucleoside that is a crucial component of the DNA salvage pathway and a building block for DNA synthesis.

Altretamine

An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.

DaxibotulinumtoxinA

DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. … _C. botulinum_ is known to produce toxins that can cause botulism in humans.

Prademagene zamikeracel

[L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … and wounds.

Imlifidase

[A225836,A225921] Imlifidase is a cysteine protease and eliminates Fc-dependent effector functions such as CDC and ADCC by cleaving the heavy chains of human immunoglobulin G (IgG) antibodies. … [A225836] As a result, highly sensitized individuals experience marked delays on transplant lists due to the challenges associated with procuring an HLA compatible donor graft.

Treosulfan

[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575] … Treosulfan is a prodrug alternative to [busulfan] for myeloablative conditioning prior to hematopoietic stem cell transplantation.

Mavorixafor

by a reduced number of mature neutrophils and lymphocytes. … [L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized